- Home
- ENVB vs ADTX Comparison
ENVB vs ADTX Comparison
Compare ENVB & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- ADTX
- Stock Information
- Founded
- ENVB 1994
- ADTX 2017
- Country
- ENVB United States
- ADTX United States
- Employees
- ENVB N/A
- ADTX N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- ADTX Health Care
- Exchange
- ENVB Nasdaq
- ADTX Nasdaq
- Market Cap
- ENVB 3.1M
- ADTX 3.1M
- IPO Year
- ENVB N/A
- ADTX 2020
- Fundamental
- Price
- ENVB $1.27
- ADTX $1.35
- Analyst Decision
- ENVB Strong Buy
- ADTX
- Analyst Count
- ENVB 1
- ADTX 0
- Target Price
- ENVB $10.00
- ADTX N/A
- AVG Volume (30 Days)
- ENVB 225.8K
- ADTX 104.0K
- Earning Date
- ENVB 08-11-2025
- ADTX 08-18-2025
- Dividend Yield
- ENVB N/A
- ADTX N/A
- EPS Growth
- ENVB N/A
- ADTX N/A
- EPS
- ENVB N/A
- ADTX N/A
- Revenue
- ENVB N/A
- ADTX $55,323.00
- Revenue This Year
- ENVB N/A
- ADTX $15,768.94
- Revenue Next Year
- ENVB N/A
- ADTX N/A
- P/E Ratio
- ENVB N/A
- ADTX N/A
- Revenue Growth
- ENVB N/A
- ADTX N/A
- 52 Week Low
- ENVB $1.01
- ADTX $1.33
- 52 Week High
- ENVB $11.55
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- ENVB 46.13
- ADTX 33.20
- Support Level
- ENVB $1.18
- ADTX $1.34
- Resistance Level
- ENVB $1.30
- ADTX $1.63
- Average True Range (ATR)
- ENVB 0.07
- ADTX 0.09
- MACD
- ENVB 0.02
- ADTX 0.07
- Stochastic Oscillator
- ENVB 50.00
- ADTX 6.67
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.